US FDA declines to approve Merck's chronic cough drug
Send a link to a friend
[December 21, 2023]
(Reuters) -The U.S. Food and Drug Administration (FDA) declined
to approve Merck's drug for chronic cough, the company said on
Wednesday, marking the second rejection in less than two years.
The health regulator concluded the company's application for the drug,
gefapixant, did not meet substantial evidence of effectiveness for
treating refractory chronic cough and unexplained chronic cough.
Currently, there are no approved treatments in the United States for
coughing bouts that don't go away despite treatment of underlying
conditions or have no identifiable cause.
The condition is estimated to affect up to 13% of the global adult
population.
In November, the agency's advisory committee panel voted 12 to 1 against
the late-stage data submitted for gefapixant, on concerns over how well
it works.
The FDA's decision was not related to the drug's safety, Merck said,
adding that it is reviewing the agency's feedback to determine next
steps.
Failing to secure marketing approval the first time, Merck carried out
additional efficacy analyses of the drug to address questions raised by
the health regulator. The results from the additional analyses were
generally consistent with those from the late-stage trial, Merck said.
![](http://archives.lincolndailynews.com/2023/Dec/21/images/ads/current/xamis_sda_HFH_2023.png)
[to top of second column]
|
![](../images/122123PIX/health90.jpg)
The Merck logo is seen at a gate to the Merck & Co campus in Rahway,
New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo
![](http://archives.lincolndailynews.com/2023/Dec/21/images/ads/current/peasleymemorials_lda_2022.png) The FDA's decision gives some
breathing room to rival GSK's chronic cough treatment camlipixant,
which is in late-stage development with anticipated regulatory
approval and launch in 2026.
Merck's gefapixant works by blocking receptors that stimulate the
nerves and trigger the urge to cough.
The drug, which was given twice a day, was evaluated across two
late-stage trials where a higher dose showed statistically
significant reduction in the average number of coughs per hour over
a 24-hour period compared to a placebo, according to Merck.
The European Union and Japan have approved Merck's drug for the
condition and it is sold under the brand name Lyfnua.
(Reporting by Christy Santhosh, Khushi Mandowara and Sriparna Roy in
Bengaluru; Editing by Tasim Zahid and Shounak Dasgupta)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |